In terms of gender, the proportion of female patients was 32.7% for RAS wt/BRAF wt, 58.6% for RAS mt/BRAF wt, and 50% for RAS wt/BRAF mt in pMMR/MSS/MSI‐low CRC, and 63.6% for RAS wt/BRAF wt, 20% for RAS mt/BRAF wt, and 66.7% for RAS wt/BRAF mt in dMMR/MSI‐high CRC cases. This evidence concerns the gene BRAF and colorectal carcinoma.